Title
CRISPR-Cas9 gene editing and human diseases
Authors
Chaitra Jinka*1,2, Chithirala Sainath3, Shyamaladevi Babu4*, Chennupati Ashok Chakravarthi5, Muppidi Lakshmi Prasanna6, Madhan Krishnan4, Gayathri Sekar7, Mayilvanan Chinnaiyan8 & Andugula Swapna Kumari9
Affiliation
1Department of Animal Biotechnology, Sri Venkateswara University, Tirupati – 517502; 2Syngene International Limited, Biocon park, Bangalore, Karnataka, India; 3Department of Zoology, Sri Venkateswara University, Tirupati- 517502; 4Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India; 5Department of Physiotherapy, KIMS College of Physiotherapy, KIMS & RF, Amalapuram, Andhra Pradesh; 6Department of Obstetrics and Gynecological Nursing, KIMS College Of Nursing, KIMS & RF, Amalapuram; 7Department of pathology, Biosciences research Foundation, Chennai, Tamilnadu, India; 8Department of Otolaryngology, University of Oklahoma Health Sciences Center, Oklahoma City, USA; 9KIMS College of Nursing, KIMS & RF, Amalapuram, East Godavari district, Andhra Pradesh, India; *Corresponding author
Chaitra Jinka - E-mail: jinka.chaitra@gmail.com
Chithirala Sainath - E-mail: sainath272@gmail.com
Shyamaladevi Babu - E-mail: shyamdevi06@gmail.com & dr.shyamaladevi@care.edu.in
Chennupati ashok Chakravarthi - E-mail: chennupati.ashok1@gmail.com
Muppidi Lakshmi Prasanna - E-mail: muppidi.prasanna24 @gmail.com
Madhan Krishnan - E-mail: kmadhan91@gmail.com & drmadhan@care.edu.in
Gayathri Sekar - E-mail: gayathrisekar2108@gmail.com
Andugula Swapna Kumari - E-mail: swapna.agp1@gmail.com; nursing.kims@gmail.com
Mayilvanan Chinnaiyan - E-mail: mayilcmn@gmail.com
Article Type
Research Article
Date
Received November 1, 2022; Revised November 29, 2022; Accepted November 30, 2022, Published November 30, 2022
Abstract
CRISPR/Cas-9 mediated genome editing has recently emerged as a potential and innovative technology in therapeutic development and biomedical research. Several recent studies have been performed to understand gene modification techniques in obtaining effective ex vivo results. Generally, the disease targets for gene correction will be in specific organs, so understanding the complete potential of genomic treatment methods is essential. From such a perspective, the present review revealed the significant importance of the CRISPR/ Cas9 delivery system. Both the promising gene-editing delivery systems, such as synthetic (non-viral) and viral vector systems are discussed in this review. In addition, this paper attempted to summarize the tissue-specific and organ-specific mRNA delivery systems that provide possible research information for future researchers. Further, the major challenges of the CRISPR/Cas9 system, such as off-target delivery, immunogenicity, and limited packaging, were also elucidated. Accordingly, this review illustrated a wide range of clinical applications associated with the efficient delivery of CRISPR/ Cas9 gene-editing. Moreover, this article emphasizes the role of the CRISPR/Cas9 system in treating Intra Cerebral haemorrhage (ICH), thereby suggesting future researchers to adopt more clinical trials on this breakthrough delivery system.
Keywords
CRISPR-Cas9, ICH, gene editing, viral vector system, non-viral vector system
Citation
Jinka et al. Bioinformation 18(11): 1081-1086 (2022)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
